The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.
about
Molecular biology of hepatitis B virus infectionImmune Tolerant Chronic Hepatitis B: The Unrecognized RisksUnderstanding the Complex Patterns Observed during Hepatitis B Virus Therapy.Superinfection with woodchuck hepatitis virus strain WHVNY of livers chronically infected with strain WHV7Animal models and the molecular biology of hepadnavirus infectionCapacity of a natural strain of woodchuck hepatitis virus, WHVNY, to induce acute infection in naive adult woodchucks.Hepadnavirus Genome Replication and Persistence.Modelling the Impact of Cell-To-Cell Transmission in Hepatitis B Virus.Present and future therapies of hepatitis B: From discovery to cureDetection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection.Monotherapy versus combination therapy for the treatment of chronic hepatitis B.Why do viruses cause cancer? Highlights of the first century of human tumour virology.Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.Infection Patterns Induced in Naive Adult Woodchucks by Virions of Woodchuck Hepatitis Virus Collected during either the Acute or Chronic Phase of Infection.HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways.The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans.A multi-scale spatial model of hepatitis-B viral dynamics.Relative Abundance of Integrant-Derived Viral RNAs in Infected Tissues Harvested from Chronic Hepatitis B Virus Carriers.
P2860
Q28083478-9CF28C41-CF03-404F-A288-DB6A48B57A02Q33753902-82AD8D14-B3E1-45F6-96C7-B05144A64C20Q33753991-9CD65ABD-8F3B-4BD9-B73A-06709D1AB6AAQ34992624-3AEFEA01-F48C-4962-B0CD-8A139C36303FQ35245221-139DC40F-89F1-4654-8F4C-24ACF24603EBQ35751930-91CD5560-B43C-44E9-8FA6-CEBDA52F35B9Q35795545-96593C61-A34E-4AE5-9673-79F01EA2CE44Q36113029-A07DF83A-6330-4C77-A3C2-746E2DE7E71AQ36378278-A2DAC4CB-183E-4011-9E52-5927BBAF8961Q37333714-658AB963-278A-4E6C-AD63-B86D0C8C8150Q37620354-8289DEDF-99E9-47F9-B7DC-77CED7052E9CQ37811898-A4DE6812-9E20-470C-8D8E-40BED52C1879Q38769680-2977094F-F28D-42AA-AC13-1D25BF4FDDCFQ40847895-4DA91B50-F83D-4049-913A-070358989597Q41930702-80637450-41A1-4CF5-9978-2C231C71DBA3Q47131005-4316F54E-E9AB-47CC-836C-9B13ACBC0FBCQ47151335-DD13BDF9-6206-42EC-9D8A-608AFEC15AC8Q54264663-E71CECB4-57A1-48CB-807C-D73728E046EB
P2860
The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The amount of hepatocyte turno ...... was inhibited with entecavir.
@en
The amount of hepatocyte turno ...... was inhibited with entecavir.
@nl
type
label
The amount of hepatocyte turno ...... was inhibited with entecavir.
@en
The amount of hepatocyte turno ...... was inhibited with entecavir.
@nl
prefLabel
The amount of hepatocyte turno ...... was inhibited with entecavir.
@en
The amount of hepatocyte turno ...... was inhibited with entecavir.
@nl
P2093
P2860
P356
P1433
P1476
The amount of hepatocyte turno ...... n was inhibited with entecavir
@en
P2093
Arend Grosse
Carol E Aldrich
Catherine Scougall
Chunxiao Xu
Huey Chi Low
Jeffry Saputelli
Richard Colonno
Sam Litwin
William S Mason
P2860
P304
P356
10.1128/JVI.01587-08
P407
P577
2008-12-10T00:00:00Z